Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine

This study has been completed.
Ortho-McNeil Janssen Scientific Affairs, LLC
Information provided by (Responsible Party):
Buchanan, Robert W., National Institute of Mental Health (NIMH) Identifier:
First received: March 14, 2003
Last updated: June 12, 2012
Last verified: June 2012
Results First Received: March 23, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Schizophrenia
Interventions: Drug: Placebo
Drug: Risperdal

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Though funding was in place beginning in 2001, recruitment took place from 2003 to 2008. Subjects were recruited from the Maryland Psychiatric Research Center Outpatient Reseach clinic, the Treatment Research Program, and community mental health centers.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
86 Participants signed informed consent. 15 were ineligible or excluded. 71 Participants entered the evaluation phase. Two were withdrawn prior to randomization. Four people withdrew after randomization but prior to starting study medications.

Reporting Groups
Risperidone Participants assigned to risperidone
Placebo Participants assigned to placebo

Participant Flow:   Overall Study
    Risperidone     Placebo  
STARTED     30     35  
COMPLETED     25     28  
NOT COMPLETED     5     7  

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Risperidone Participants assigned to risperidone
Placebo Participants assigned to placebo
Total Total of all reporting groups

Baseline Measures
    Risperidone     Placebo     Total  
Number of Participants  
[units: participants]
  30     35     65  
[units: participants]
<=18 years     0     0     0  
Between 18 and 65 years     30     35     65  
>=65 years     0     0     0  
[units: years]
Mean ± Standard Deviation
  48.3  ± 7.2     44.1  ± 9.3     46.1  ± 8.6  
[units: participants]
Female     11     10     21  
Male     19     25     44  
Region of Enrollment  
[units: participants]
United States     30     35     65  

  Outcome Measures

1.  Primary:   Brief Psychiatric Rating Scale (BPRS)   [ Time Frame: Measured at baseline and every 2 weeks for 16 weeks ]

2.  Secondary:   Neuropsychological Testing   [ Time Frame: Measured at baseline and Week 16 ]
Results not yet reported.   Anticipated Reporting Date:   08/2009   Safety Issue:   No

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Robert W. Buchanan, MD
Organization: Maryland Psychiatric Research Center
phone: 410-402-7876

No publications provided by National Institute of Mental Health (NIMH)

Publications automatically indexed to this study:

Responsible Party: Buchanan, Robert W., National Institute of Mental Health (NIMH) Identifier: NCT00056498     History of Changes
Other Study ID Numbers: R01 MH045074, DSIR 83-ATAP
Study First Received: March 14, 2003
Results First Received: March 23, 2009
Last Updated: June 12, 2012
Health Authority: United States: Federal Government